scholarly journals Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin's disease

1997 ◽  
Vol 75 (7) ◽  
pp. 1044-1048 ◽  
Author(s):  
C Rubio ◽  
ME Hill ◽  
S Milan ◽  
MER O'Brien ◽  
D Cunningham
Keyword(s):  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Idiopathic Pneumonia Syndrome

High Dose Chemotherapy (HDC) and Non Frozen ABMT in Refractory Hodgkin’s Disease (HD)

1985 ◽  
pp. 23-24
Author(s):  
A. M. Carella ◽  
G. Santini ◽  
F. Frassoni ◽  
A. Santoro ◽  
P. Coser ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
High Dose Chemotherapy ◽  
High Dose

Gemcitabine in the Treatment of Refractory Hodgkin’s Disease: Results of a Multicenter Phase II Study

2000 ◽  
Vol 18 (13) ◽  
pp. 2615-2619 ◽  
Author(s):  
A. Santoro ◽  
H. Bredenfeld ◽  
L. Devizzi ◽  
H. Tesch ◽  
V. Bonfante ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Response Rate ◽  
Hodgkin’S Disease ◽  
Autologous Bone Marrow ◽  
Disease Status ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Efficacy Analysis ◽  
Duration Of Response ◽  
Heavily Pretreated

PURPOSE: To explore the use of gemcitabine for the treatment of patients with relapsing or refractory Hodgkin’s disease. PATIENTS AND METHODS: Eligible patients had measurable disease and more than one previous chemotherapy regimen. Patients previously treated with high-dose chemotherapy with autologous bone marrow or peripheral stem-cell support were not included. Gemcitabine, 1,250 mg/m2, was administered as a 30-minute intravenous infusion on days 1, 8, and 15 of each 28-day cycle of therapy. The dosing schedule remained fixed, and any dose of gemcitabine that could not be given on time was omitted. Patients who had not experienced any hematologic or nonhematologic toxicity after one complete cycle of therapy were permitted to have subsequent doses increased by 20%: that is, from 1,250 mg/m2 to 1,500 mg/m2. RESULTS: Of the 23 enrolled patients, 22 were assessable for response; all 23 patients were included in the efficacy analysis. Disease status for two patients (9%) reached a state of complete remission, and seven patients (30%) achieved a partial response, for an overall response rate of 39% (95% confidence interval, 19.7% to 61.5%). The likelihood of achieving a response was not influenced by a patients’ main pretreatment characteristics or by their response to their last prior chemotherapy. The median duration of response was 6.7 months (range, 2 to 33+ months), and the median overall survival time was 10.7 months (range, 4 to 34.7+ months). In general, toxicities were mild; no treatment-related deaths occurred, and only one life-threatening adverse event was reported for this study. CONCLUSION: Gemcitabine was shown to be active in heavily pretreated patients with Hodgkin’s disease, producing a response rate of 39%. Additionally, drug-related toxicities were mild, which thus suggests the possible inclusion of gemcitabine in an earlier phase of treatment.

Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease.

1989 ◽  
Vol 7 (12) ◽  
pp. 1791-1799 ◽  
Author(s):  
K M Taylor ◽  
S Jagannath ◽  
G Spitzer ◽  
J A Spinolo ◽  
S L Tucker ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Autologous Bone Marrow Transplantation ◽  
Autologous Bone Marrow ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Granulocyte Colony Stimulating Factor ◽  
Autologous Bone ◽  
Stimulating Factor ◽  
Historical Controls

To determine whether recombinant human granulocyte colony-stimulating factor (rhG-CSF) can accelerate granulocyte recovery after high-dose combination chemotherapy with autologous bone marrow transplantation (ABMT) in patients with Hodgkin's disease, we performed a nonrandomized phase II study using historical controls as a comparison. Eighteen relapsed/refractory Hodgkin's disease patients who received cyclophosphamide at 1.5 g/m2/day (days -6 to -3), carmustine (BCNU) at 300 mg/m2 (day -6), and etoposide (VP-16) at 125 mg/m2 every 12 hours (days -6 to -4), followed by ABMT (day 0) were treated with rhG-CSF at 60 micrograms/kg/day for a maximum of 28 days beginning on day 1. rhG-CSF dosage was gradually diminished and stopped once an adequate granulocyte count was maintained. rhG-CSF significantly accelerated absolute granulocyte count (AGC) compared with historical controls recovery to the 100/microL level (median, 9 days v 13 days; P = .103 x 10(-4), 500/microL level (median, 13 days v 22 days; P = 0.189 x 10(-2), and 1000/microL level (median, 16 days v 30 days levels; P = .125 x 10(-5). Platelet recovery to 50,000/microL was not significantly altered (P = .370). rhG-CSF was well tolerated, bone pain and myalgia being the only side effects noted. rhG-CSF hastens granulocyte recovery after high-dose chemotherapy with ABMT in patients with relapsed/refractory Hodgkin's disease without significant toxicity.

Hodgkin’s disease and HIV infection (HD-HIV): Prognostic factors in 596 patients (pts) within the group of European Cooperation on AIDS and Tumors (GECAT).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 8058-8058
Author(s):  
Michele Spina ◽  
Josep-Maria Ribera ◽  
Jean Gabarre ◽  
Christoph Wyen ◽  
Silvia Montoto ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Hiv Infection ◽  
Highly Active Antiretroviral Therapy ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Cd4 Cell Count ◽  
Highly Active ◽  
Cd4 Cell

8058 Background: Hodgkin’s disease (HD) is the most common non-AIDS defining tumour diagnosed in HIV setting. The introduction of highly active antiretroviral therapy (HAART) has opened a new prospective in the treatment of pts with HD-HIV as the better control of the underlying HIV infection allows the use of more aggressive chemotherapy regimens, including high dose chemotherapy. However, up to now prognostic factors on overall survival (OS) or time to treatment failure (TTF) have not yet been identified. Methods: In order to identify prognostic factors, we analyzed data on 596 pts with HD-HIV diagnosed and treated in 90 different Institution of 6 European countries from October 1983 to March 2010. All factors were analyzed for OS and TTF. Results: 86% of pts were male and the median CD4 cell count was 224/dl (range 3-1274); 52% of pts had mixed cellularity subtype, stages III-IV were diagnosed in 72% of cases and 55% of pts had extranodal involvement (bone marrow 35%, spleen 21%, liver 14%). The table summarizes the results of multivariate analysis. Conclusions: We identified a new “European Score” for HD-HIV able to predict different outcomes in these patients. This score should be considered for future prospective studies. [Table: see text]

scholarly journals Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy

2004 ◽  
Vol 33 (12) ◽  
pp. 1225-1229 ◽  
Author(s):  
J Czyz ◽  
R Szydlo ◽  
W Knopinska-Posluszny ◽  
A Hellmann ◽  
J Gozdzik ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Conventional Therapy ◽  
Hodgkin’S Disease ◽  
High Dose Chemotherapy ◽  
High Dose

High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease

1993 ◽  
Vol 66 (5) ◽  
pp. 251-256 ◽  
Author(s):  
N. Schmitz ◽  
B. Glass ◽  
P. Dreger ◽  
T. Haferlach ◽  
H. -A. Horst ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Hematopoietic Stem ◽  
Stem Cell Rescue
Sign in / Sign up

Export Citation Format

Share Document